Results 11 to 20 of about 13,054 (213)

Sodium Butyrate Enhances the Cytotoxic Effect of Etoposide in HDACi-Sensitive and HDACi-Resistant Transformed Cells

International Journal of Molecular Sciences, 2023
To overcome the problem of antitumor agent toxicity for normal cells, a combined therapy using drugs with synergistic effects seems to be more effective. We investigated the molecular mechanisms of the sensitization of tumor cells resistant and sensitive to histone deacetylase inhibitors (HDACis) upon etoposide treatment together with the HDACi sodium ...
Olga O. Gnedina, Alisa V. Morshneva, Maria V. Igotti   +2 more
openaire   +3 more sources

HDACi

Journal of Dental Research, 2011
Acetylation of histone and non-histone proteins alters gene expression and induces a host of cellular effects. The acetylation process is homeostatically balanced by two groups of cellular enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs).
Duncan, H F, Smith, A J, Fleming, G J P, Cooper, P R   +3 more
openaire   +4 more sources

Histone Deacetylase Inhibitor (HDACi) Conjugated Polycaprolactone for Combination Cancer Therapy [PDF]

Biomacromolecules, 2018
The short chain fatty acid, 4-phenylbutyric acid (PBA), is used for the treatment of urea cycle disorders and sickle cell disease as an endoplasmic reticulum stress inhibitor. PBA is also known as a histone deacetylase inhibitor (HDACi). We report here the effect of combination therapy on HeLa cancer cells using PBA as the HDACi together with the ...
Ruvanthi N. Kularatne, Katherine E. Washington, Chandima Bulumulla, Erika L. Calubaquib, Michael C. Biewer, David Oupicky, Mihaela C. Stefan   +6 more
openaire   +3 more sources

ID3 deficiency alters chromatin accessibility at DSB sites and enhances vulnerability to HDAC inhibition. [PDF]

Int J Cancer
What's new? Errors in DNA double‐strand break (DSB) repair can lead to mutations, chromosomal instability, and ultimately cancer. Inhibitor of DNA‐binding 3 (ID3), a transcriptional repressor, is crucial to promoting DSB repair and helping maintain genome stability. Here, the authors investigated ID3 regulation of DNA repair via chromatin accessibility
Corte GD, Eldesouky H, Puchan J, Öz S, Everatt E, Goyal A, Sigismondo G, Oppermann U, Plass C, Weichenhan D, Bakr A.   +10 more
europepmc   +2 more sources

The Role of HDACs and HDACi in Cartilage and Osteoarthritis [PDF]

Frontiers in Cell and Developmental Biology, 2020
Epigenetics plays an important role in the pathogenesis and treatment of osteoarthritis (OA). In recent decades, HDAC family members have been associated with OA. This paper aims to describe the different role of HDACs in the pathogenesis of OA through interaction with microRNAs and the regulation of relevant signaling pathways. We found that HDACs are
He Zhang, Lu Ji, Yue Yang, Xiaoning Zhang, Yi Gang, Lunhao Bai   +5 more
openaire   +3 more sources

Synthesis and characterisation of novel isoform-selective histone deacetylase inhibitors (HDACi) and HDACi-based multi-target ligands [PDF]

, 2022
In the quickly evolving field of epigenetic therapy, histone deacetylases (HDACs) have emerged as preferred targets for the treatment of cancer and other conditions such as viral infections, neurodegenerative disorders, and inflammatory diseases.
Reßing, Nina Jacqueline
core   +1 more source

CLU blocks HDACI-mediated killing of neuroblastoma [PDF]

Tumor Biology, 2010
Clusterin is a ubiquitously expressed glycoprotein with multiple binding partners including IL-6, Ku70, and Bax. Clusterin blocks apoptosis by binding to activated Bax and sequestering it in the cytoplasm, thereby preventing Bax from entering mitochondria, releasing cytochrome c, and triggering apoptosis.
Subramanian, Chitra, Jarzembowski, Jason A., Halsey, Sonja M., Kuick, Rork, Opipari, Anthony W., Castle, Valerie P., Kwok, Roland P. S.   +6 more
openaire   +2 more sources

Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy. [PDF]

PLoS ONE, 2014
Histone deacetylase inhibitors (HDACi) can induce human immunodeficiency virus (HIV) transcription from the HIV long terminal repeat (LTR). However, ex vivo and in vivo responses to HDACi are variable and the activity of HDACi in cells other than T-cells
Hao K Lu, Lachlan R Gray, Fiona Wightman, Paula Ellenberg, Gabriela Khoury, Wan-Jung Cheng, Talia M Mota, Steve Wesselingh, Paul R Gorry, Paul U Cameron, Melissa J Churchill, Sharon R Lewin   +11 more
doaj   +1 more source

HDACi - going through the mechanisms

Frontiers in Bioscience, 2011
Histone deacetylases inhibitors (HDACi) have recently emerged as potent antitumor treatment modality. They are currently tested in many phase I, II and III clinical trials as single agents as wells as in combination schemes. They have demonstrated promising antitumor activity and favorable clinical outcome.
Malgorzata, Wanczyk, Katarzyna, Roszczenko, Katarzyna, Marcinkiewicz, Kamil, Bojarczuk, Michal, Kowara, Magdalena, Winiarska   +5 more
openaire   +2 more sources

HDACIs and the inhibition of invasive potential [PDF]

Cancer Biology & Therapy, 2013
A major problem in the treatment of cancer and prolongation of patient survival is the dissemination of cells from a defined tumor site into a loco-regional disease and ultimately to full metastatic spread into distant organs. In the manuscript by Ierano et al.
openaire   +2 more sources